Colchicine-induced rhabdomyolysis

Phanish, Mysore K.; Krishnamurthy, Suchitra; Bloodworth, L L

doi:10.1016/s0002-9343(02)01426-2

Cited by 21 publications

(43 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Atasoyu and co-workers (9), two different mechanisms may be responsible for the pathogenesis in our patient. Drug interactions that potentiate adverse effects may occur when colchicine is co-administered with fluvastatin since both drugs are metabolized by cytochrome P450 isoenzymes and myotoxic effects are well known (7)(8). Fluvastatin and colchicine, however, are cleared through two different CYP450 isoenzymes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rhabdomyolysis induced by co-administration of fluvastatin and colchicine

Sarullo

Americo

Pasquale

2015

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

A case of fluvastatin-induced rhabdomyolysis after coadministration of colchicine is reported. A 77 year old man with ischemic heart disease, chronic pericardial effusion, diabetes mellitus, dyslipidemia, arterial hypertension, chronic renal failure (stage 2 of classification of chronic kidney disease of National Kidney Foundation) and chronic gout presented with a generalized muscle pain. The patient had been taking 80 mg/day of fluvastatin for 4 years, and, for four weeks before presentation, he had also been taking a dose of colchicine (1.0 mg daily) for an exacerbation of gout. Investigations confirmed the diagnosis of rhabdomyolysis. Discontinuation of fluvastatin and colchicine therapy and adequate fluid administration resulted in the resolution of clinical and biochemical features of rhabdomyolysis. Although neuromuscular adverse effects of fluvastatin and colchicine are well recognized, rhabdomyolysis is rare, making this is only the second case reported of fluvastatin and colchicine co-administration induced rhabdomyolysis in literature.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Colchicine has been reported to cause myoneuropathy (5) and myotonia (6) especially in presence of renal impairment. However, rhabdomyolysis induced by colchicine is rare (7,8). Rhabdomyolysis with the use of statin-colchicine combinations has been reported only in one case (9).…”

Section: Introductionmentioning

confidence: 99%

Rhabdomyolysis induced by co-administration of fluvastatin and colchicine

Sarullo

Americo

Pasquale

2015

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…At least 9 case reports describe patients in whom myotoxicity, ranging from weakness and myopathy to fatal rhabdomyolysis, developed following the initiation of combination therapy involving colchicine and an HMG-CoA reductase inhibitor (statin). 36 -44 Reported cases have involved simvastatin, 36 -39 atorvastatin, 40,41 fluvastatin, 42 lovastatin, 43 and pravastatin. 44 Although no clear underlying patient risk factors (other than the colchicine-statin association) were present in all cases, several of the patients had at least mildly impared renal function, 36,38 -40,44 and two were transplant recipients receiving other potentially interacting drugs (i.e.…”

Section: Drug Interactionsmentioning

confidence: 99%

“…cyclosporine). 37,41 In most of the cases, muscle weakness was the initial symptom, and the initial onset of symptoms was 2-3 weeks (but as long as several months) after the initiation of the combination. The precise mechanism of this interaction is unclear, but it may have pharmacodynamic and/or pharmacokinetic components.…”

Section: Drug Interactionsmentioning

confidence: 99%

Colchicine for pericarditis: hype or hope?

Imazio

Brucato

Trinchero

et al. 2009

European Heart Journal

109

View full text Add to dashboard Cite

Colchicine has been effectively used in the treatment of several inflammatory conditions, such as gouty attacks, serositis related to familial Mediterranean fever, Behçet syndrome, and more recently also in acute and recurrent pericarditis. Growing evidence has shown that the drug may be useful to treat an acute attack and may be a way to cope with the prevention of pericarditis in acute and recurrent cases and after cardiac surgery. Nevertheless, clinicians are often sceptical about the efficacy of the drug, and concerns have risen on possible side effects and tolerability. In this review, we analyse current evidence to support the use of the drug, as well as possible harms and risks related to drug interactions, reaching the conclusion that colchicine is safe and useful in recurrent pericarditis, if specific precautions are followed, although less evidence supports its use for the treatment of acute pericarditis, where colchicine remains optional and there is a need for further multicentre confirmatory studies. This paper also reviews specific dosing and precautions for the clinical use.

show abstract

“…Of note, the fairly short duration (1 week) of symptoms prior to admission in contrast to a majority of the previous reports of the condition described and the sudden 10‐fold rise in creatinine‐kinase 1 also favour the underlying possibility of rhabdomyolysis (which can have similar histopathological findings). Colchicine‐related rhabdomyolysis is well recognized, 2,3 and tends to occur in the setting of renal failure 4,5 . Electrolyte imbalance related to diuretic therapy per se, resulting in rhabdomyolysis is well recognized, 6,7 more so with furosemide treatment 8 .…”

mentioning

confidence: 99%